Given the powerful ability of IFNα-MSCs in deployment of CD8+ T cells into tumors, we hypothesized that combination of IFNα-MSCs and PD-L1 blockade may modulate the immune context of tumor and empower more potent anti-tumor effect. This evidence concerns the gene CD8A and neoplasm.